Clinical Trial

AB122 Platform Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-06
minor Trial arms changed: 17 -> 18 2026-08-06
notable Primary completion pushed: 2026-05 -> 2027-06 2026-08-06
minor Completion pushed: 2026-05 -> 2027-06 2026-08-06
Trial Details
NCT Number NCT04999761
Lead Sponsor Taiho Pharmaceutical Co., Ltd.
Conditions Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer +1 more
Enrollment 917 participants
Start Date 2021-06-01
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-05